Innate Pharma (IPHA) Revenue (2019 - 2025)
Innate Pharma's (IPHA) quarterly Revenue came in at $3.2 million in Q4 2025, down 75.95% YoY from $13.5 million in Q4 2024, and down 75.95% on a QoQ basis from $13.5 million in Q4 2024.
Innate Pharma (IPHA) Revenue (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Revenue data on file, last reported at $3.2 million in Q4 2025.
- Quarterly Revenue fell 75.95% year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $81.5 million (down 30.19% YoY) and the FY2025 annual result came in at $10.5 million, down 51.25% from the prior year.
- Revenue retreated to $3.2 million in Q4 2025, from $13.5 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $50.6 billion in Q4 2022 to a low of $3.2 million in Q4 2025.
- A 5-year average of $6.3 billion and a median of $16.2 million in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue surged 364974.2% — and 2023, when it plunged 99.89%.
- Tracing IPHA's Revenue over 5 years: stood at $13.9 million in 2021, then surged by 364974.2% to $50.6 billion in 2022, then sank by 99.89% to $55.8 million in 2023, then plunged by 75.85% to $13.5 million in 2024, then slumped by 75.95% to $3.2 million in 2025.
- The last three Revenue figures came in at $3.2 million (Q4 2025), $13.5 million (Q4 2024), and $8.9 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Innate Pharma | 187.25 Mn | 187.25 Mn | - | 3.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.24 Mn |
| Dec 31, 2024 | 13.49 Mn |
| Jun 30, 2024 | 8.93 Mn |
| Dec 31, 2023 | 55.84 Mn |
| Jun 30, 2023 | 38.49 Mn |
| Dec 31, 2022 | 50.58 Bn |
| Jun 30, 2022 | 18.57 Mn |
| Dec 31, 2021 | 13.86 Mn |
| Dec 31, 2020 | 66.95 Mn |
| Dec 31, 2019 | 76.35 Mn |